How to Get Belsomra (Suvorexant) in South Dakota

What Is Suvorexant and Why Is It Prescribed?

Suvorexant is a dual orexin receptor antagonist (DORA) that blocks wakefulness-promoting orexin-A and orexin-B neuropeptides in the lateral hypothalamus. The FDA approved it in August 2014 for the treatment of insomnia characterized by difficulty with sleep onset and sleep maintenance [1].

Unlike benzodiazepine receptor agonists such as zolpidem, suvorexant does not act on GABA-A receptors. This distinct mechanism produced clinically meaningful improvements in both subjective total sleep time (sTST) and wake after sleep onset (WASO) in the key phase III trial by Herring et al. (Lancet Neurology, 2014), which enrolled 3,076 patients across two randomized, double-blind, placebo-controlled studies. At 40 mg (a dose later reduced by the FDA to a 20 mg maximum), patients gained a median 22 minutes of sTST over placebo at month one. The 20 mg dose, the highest approved strength, showed statistically significant separation from placebo for both sleep onset and maintenance endpoints at week four (P<0.001 for sTST and WASO) [1].

The FDA-approved prescribing information recommends starting at 10 mg no more than 30 minutes before bedtime, with at least seven hours of planned sleep remaining. The dose can be raised to 20 mg if the 10 mg dose is tolerated but not effective. That starting-dose philosophy matters for South Dakota patients initiating therapy through telehealth, because prescribers often trial 10 mg for two to four weeks before titrating.

Telehealth Prescribing for Belsomra in South Dakota

South Dakota law permits telehealth prescribing of Schedule IV controlled substances, which means licensed providers can evaluate, diagnose, and prescribe suvorexant via a synchronous audio-video visit. No in-person visit is required before the initial prescription.

South Dakota codified its telehealth parity framework under SDCL 36-36, requiring that the prescriber hold or obtain a South Dakota medical license (or multistate compact license where applicable). The provider must document the clinical encounter to the same standard as an in-office visit, including a sleep history, review of current medications, and screening for contraindications such as narcolepsy or severe hepatic impairment.

Several national telehealth platforms now serve South Dakota residents for insomnia management. A typical workflow looks like this: the patient completes an intake questionnaire covering sleep latency, total sleep time, daytime functioning, and prior medication trials. A licensed prescriber reviews the intake, conducts a live video consultation, and, if appropriate, sends an electronic prescription to a South Dakota pharmacy. Because suvorexant is Schedule IV, electronic prescribing for controlled substances (EPCS) is permitted under DEA regulations and South Dakota Board of Pharmacy rules.

For patients in rural parts of western South Dakota where the nearest sleep medicine specialist may be over 100 miles away, telehealth removes a significant barrier. According to HRSA data on health professional shortage areas, approximately 64% of South Dakota counties qualify as mental health professional shortage areas, a designation that overlaps heavily with the provider pool for insomnia care.

Who Can Prescribe Belsomra in South Dakota?

Three categories of providers hold authority to prescribe Schedule IV substances in South Dakota: physicians (MD/DO), nurse practitioners with prescriptive authority, and physician assistants practicing under a collaborative agreement.

South Dakota nurse practitioners gained full practice authority under certain conditions through legislative updates, but prescriptive authority for controlled substances still requires a DEA registration and compliance with the state Board of Nursing rules. A nurse practitioner prescribing suvorexant must hold a current South Dakota NP license, maintain a DEA registration with Schedule IV authority, and document the clinical rationale in the patient record.

Physician assistants in South Dakota prescribe controlled substances under a supervision agreement with a licensed physician. The PA's supervising physician must authorize Schedule IV prescribing within the delegation agreement. Both NPs and PAs can conduct the prescribing visit via telehealth, provided they meet the same documentation and licensing requirements that apply to physicians.

Primary care providers write the majority of insomnia prescriptions nationally. A 2019 analysis published in the Journal of Clinical Sleep Medicine found that 72.2% of hypnotic prescriptions originated from non-sleep-specialist physicians, reinforcing that South Dakota patients do not need a sleep medicine referral to access suvorexant.

South Dakota Pharmacy Access and 503A Compounding

South Dakota's pharmacy infrastructure supports both branded Belsomra dispensing and 503A compounded suvorexant preparations. Most chain pharmacies (CVS, Walgreens, Lewis Drug, and independent SD pharmacies) stock or can order Belsomra within one to two business days.

503A compounding pharmacies licensed in South Dakota can prepare suvorexant formulations for patients with a valid prescription, typically when a patient needs a dose form not commercially available (for example, a liquid suspension for patients with dysphagia). Under Section 503A of the Federal Food, Drug, and Cosmetic Act, these pharmacies compound based on individual patient prescriptions and must comply with state Board of Pharmacy regulations. South Dakota's Board of Pharmacy registers compounding pharmacies separately and conducts inspections aligned with USP standards.

For patients using telehealth, the prescriber sends the prescription electronically to the patient's preferred South Dakota pharmacy. Mail-order options are also available: several PBM-affiliated mail-order pharmacies ship Schedule IV medications to South Dakota addresses, provided the prescription meets EPCS requirements and the pharmacy holds a South Dakota nonresident license.

Insurance, Prior Authorization, and Cost in South Dakota

Belsomra carries a brand-name price that presents a real financial consideration. The average cash price ranges from $400 to $500 for a 30-tablet supply. Insurance coverage varies substantially by plan.

South Dakota Medicaid does not cover Belsomra. Patients enrolled in South Dakota Medicaid who need an orexin receptor antagonist for insomnia typically face a non-preferred or excluded status, which means the prescriber must pursue alternative agents first (usually generic zolpidem, eszopiclone, or suvorexant alternatives if available) or submit a prior authorization demonstrating medical necessity. Because generic suvorexant is not yet available (Merck's patent exclusivity extends to 2029 based on FDA Orange Book data), Medicaid denial rates for Belsomra remain high.

Commercial insurers in South Dakota, including Avera Health Plans, Sanford Health Plan, and nationally administered plans through UnitedHealthcare or Blue Cross Blue Shield of South Dakota, generally place Belsomra on a non-preferred specialty tier. Prior authorization criteria typically require documentation of:

1. A confirmed insomnia diagnosis (ICD-10 G47.00 or G47.01)
2. Failure or intolerance of at least one first-line generic hypnotic (zolpidem, eszopiclone, or doxepin low-dose)
3. A clinical reason why the failed agent is not appropriate for continued use
4. Absence of contraindications (narcolepsy, severe hepatic impairment, concurrent use of strong CYP3A inhibitors)

The Merck savings card program reduces out-of-pocket costs for commercially insured patients to as low as $0 per month for eligible fills, with annual caps that vary by program year. Uninsured patients can apply for the Merck Patient Assistance Program, which provides Belsomra at no cost to qualifying low-income individuals [2].

What Labs or Evaluations Are Needed Before Starting Belsomra?

Suvorexant does not require routine laboratory monitoring before or during therapy. No blood tests are mandated by the FDA label. The prescribing evaluation is clinical: a focused sleep history, medication reconciliation, and screening for conditions that contraindicate the drug.

Key clinical checkpoints before prescribing include:

Hepatic function. Suvorexant is extensively metabolized by CYP3A4. The FDA label recommends caution in moderate hepatic impairment and contraindicates use in severe hepatic impairment. If a patient has known liver disease or risk factors (heavy alcohol use, hepatitis), a CMP or hepatic panel is reasonable but not universally required [2].

Drug interaction review. Concurrent use of strong CYP3A inhibitors (ketoconazole, itraconazole, clarithromycin, ritonavir) is contraindicated. Moderate CYP3A inhibitors (verapamil, diltiazem, fluconazole) require a dose reduction to 5 mg, though 5 mg is not a commercially available standalone tablet, creating a practical barrier. The prescriber should conduct a thorough medication review.

Sleep apnea screening. The American Academy of Sleep Medicine clinical practice guideline (2017) recommends that clinicians screen for obstructive sleep apnea before initiating any pharmacologic insomnia treatment, because hypnotic medications may worsen respiratory depression in undiagnosed OSA. The STOP-Bang questionnaire is the most widely used screening tool in primary care and telehealth settings.

Depression and suicidality assessment. The Belsomra label carries a warning regarding worsening depression and suicidal ideation. A PHQ-9 or equivalent screen is standard practice, particularly in telehealth encounters where the provider cannot observe physical affect as easily.

Timeline: How Long Until You Receive Belsomra in South Dakota?

For most patients, the process from initial consultation to medication in hand takes three to seven business days when no prior authorization complications arise. Here is a realistic breakdown.

Day one: telehealth visit completed, prescription sent electronically. Day one to two: pharmacy receives and verifies the EPCS prescription. If the pharmacy has Belsomra in stock, the patient can pick it up the same or next business day. If the pharmacy needs to order it, add one to two business days for wholesaler delivery.

When prior authorization is required, add three to five business days for the insurer to process the request. South Dakota does not have a state-mandated prior authorization response timeline for commercial plans, but most insurers follow a 72-hour standard turnaround for non-urgent requests. Urgent requests (defined as situations where a delay could seriously jeopardize the patient's health) are typically processed within 24 hours.

Mail-order pharmacy fulfillment adds an additional two to five business days for shipping after prescription adjudication. Patients in remote areas of South Dakota may prefer mail order for the convenience of home delivery.

Transferring a Belsomra Prescription to South Dakota

Patients relocating to South Dakota or visiting for an extended period can transfer an existing Belsomra prescription from another state. Under DEA regulations governing Schedule IV transfers, a prescription can be transferred between pharmacies one time only (unless both pharmacies share a real-time online database, in which case multiple transfers are permitted within the prescription's valid period).

The receiving South Dakota pharmacy contacts the originating pharmacy to verify the prescription details, remaining refills, and prescriber information. South Dakota Board of Pharmacy rules align with federal transfer requirements. The transfer must be documented by both pharmacies, and the originating pharmacy must void its remaining fills.

Patients using a national chain pharmacy (CVS, Walgreens) often experience smoother transfers because these chains share centralized prescription databases, allowing the prescription to move within the system without the single-transfer limitation.

For patients whose prescriptions originate from an out-of-state telehealth provider, the telehealth prescriber must hold (or obtain) a South Dakota license to write new prescriptions dispensed in the state. A prescription already written and on file at an out-of-state pharmacy can be transferred to a South Dakota pharmacy without the prescriber being SD-licensed, because the transfer is a pharmacy-to-pharmacy transaction governed by the state where the prescription was originally dispensed.

Suvorexant vs. Other Insomnia Medications Available in South Dakota

South Dakota patients and prescribers weighing suvorexant against alternatives should consider efficacy data, cost, and formulary status side by side.

Generic zolpidem (Ambien) remains the most prescribed insomnia medication nationally and costs $5 to $15 for a 30-day supply. It acts on GABA-A receptors and carries known risks of complex sleep behaviors (sleep-driving, sleep-eating). The FDA added a boxed warning to zolpidem in 2019 after reports of fatal injuries during parasomnias.

Lemborexant (Dayvigo), a second DORA, was approved in December 2019. In the SUNRISE-2 trial (N=949), lemborexant 5 mg and 10 mg both significantly improved sTST and WASO versus placebo over 12 months. Head-to-head data comparing lemborexant directly with suvorexant are limited to the SUNRISE-1 trial, which used zolpidem as an active comparator rather than suvorexant. Both DORAs share a similar mechanism, and formulary position in South Dakota varies by plan.

Low-dose doxepin (Silenor, 3 mg and 6 mg) is FDA-approved for sleep maintenance insomnia and is available generically at $10 to $30 per month. It has a different mechanism (histamine H1 antagonism at low doses) and may be preferred for patients with contraindications to orexin antagonists.

The AASM 2017 clinical practice guideline gives suvorexant a "WEAK FOR" recommendation for both sleep onset and sleep maintenance insomnia, noting moderate-quality evidence. Dr. Michael Sateia, lead author of the guideline, stated: "We recommend suvorexant for sleep maintenance insomnia, though the strength of recommendation is conditional, reflecting moderate evidence quality and the need for individual risk-benefit evaluation" [3].

Practical Tips for South Dakota Patients

Start the process by confirming your insurance formulary status for Belsomra before booking a telehealth visit. Call the member services number on your insurance card and ask whether suvorexant requires prior authorization and what step therapy criteria apply.

If your plan requires a generic trial first, discuss with your prescriber whether a 7- to 14-day trial of generic zolpidem or eszopiclone (with documented outcomes) satisfies the step therapy requirement. Some insurers accept a documented intolerance or contraindication in lieu of an actual trial.

Keep a sleep diary for at least one week before your appointment. The National Sleep Foundation consensus panel recommends that adults aim for seven to nine hours of sleep per night, and a diary that documents sleep latency greater than 30 minutes or wake episodes exceeding 30 minutes supports the insomnia diagnosis and strengthens the prior authorization submission.

South Dakota residents without insurance should request the Merck Patient Assistance Program application directly from their prescriber or download it from the manufacturer's website. Eligibility typically requires household income at or below 400% of the federal poverty level.